Assess whether to resubmit, meet, or pause the program (b4e4c4)

SITUATION The working file is RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings. CMC change-control owner in a mid-size sponsor after a complete response letter has to name To resubmit, meet, or Pause the program for this Pharma & Life Sciences Pharmacovigilance file.

DECISION CMC change-control owner in a mid-size sponsor after a complete response letter must choose To resubmit, meet, / Pause the program using RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. The population in RWE protocol that may not meet regulator expectations is the one an AdCom briefing document that overstates subgroup findings named, so To resubmit, meet, follows for this Pharmacovigilance file. 2. The population in RWE protocol that may not meet regulator expectations is adjacent only to an AdCom briefing document that overstates subgroup findings; Pause the program is the honest Pharma & Life Sciences call. 3. A mid-size sponsor after a complete response letter already contained an AdCom briefing document that overstates subgroup findings before RWE protocol that may not meet regulator expectations arrived; no new Pharmacovigilance path. 4. Provenance on RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings is broken; do not pick To resubmit, meet, or Pause the program yet.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 2. Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to resubmit, meet, or for CMC change-control owner.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings). The follow-on Pharmacovigilance action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in RWE protocol that may not meet regulator expectations, then the action for CMC change-control owner - Hypothesis scorecard against RWE protocol that may not meet regulator expectations: supported / rejected / untestable - Owner and next date for CMC change-control owner in a mid-size sponsor after a complete response letter - What changes to resubmit, meet, or if an AdCom briefing document that overstates subgroup findings is later withdrawn